LivaNova (LIVN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.26
- Estimate
- $1.09
- Surprise
- +15.1%
- Revenue (period 2026-06-30)
- $390.6M
- Score today
- 6.5/10
Revenue source: xbrl.
How the report landed
LivaNova (LIVN) beat the $1.09 estimate with diluted EPS of $1.26 — a large 15.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LIVN Hold at 6.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +15.1% surprise compares with a +12.6% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.5% away)
- Target reached (-5.4% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $81.96
- Price target
- $94.23
- Stop
- $77.59
- Upside to target
- +15.0%
The stock trades at 24.3× trailing but 17.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
LIVN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $4.46B
- P/E (fwd)
- 17.4
- P/E (ttm)
- 24.3
- 52-week range
- $48.82–$85.76
- Off 52-week high
- 4.4%
- RSI (14)
- 52
- Volume vs avg
- 0.22×
- Score today
- 6.5/10